ProCE Banner Activity

MURANO Interim Analysis: Venetoclax + Rituximab vs Bendamustine + Rituximab in Patients With Relapsed/Refractory CLL

Slideset Download
Conference Coverage
In a preplanned interim analysis of this phase III study, venetoclax plus rituximab significantly improved median PFS independent of del(17p) status vs bendamustine plus rituximab, with 60% of patients maintaining MRD negativity at 18 months.

Released: December 15, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology